1. Home
  2. PHUN vs VERU Comparison

PHUN vs VERU Comparison

Compare PHUN & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phunware Inc.

PHUN

Phunware Inc.

HOLD

Current Price

$2.04

Market Cap

44.4M

Sector

Technology

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.34

Market Cap

40.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHUN
VERU
Founded
2009
1971
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.4M
40.9M
IPO Year
2016
1996

Fundamental Metrics

Financial Performance
Metric
PHUN
VERU
Price
$2.04
$2.34
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$7.25
$22.50
AVG Volume (30 Days)
131.6K
59.8K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
39.36
N/A
EPS
N/A
N/A
Revenue
$30,883,000.00
$16,296,958.00
Revenue This Year
$89.86
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
15.57
N/A
52 Week Low
$1.56
$0.36
52 Week High
$3.88
$4.59

Technical Indicators

Market Signals
Indicator
PHUN
VERU
Relative Strength Index (RSI) 49.66 56.27
Support Level $1.79 $2.12
Resistance Level $2.28 $2.67
Average True Range (ATR) 0.11 0.12
MACD -0.01 0.02
Stochastic Oscillator 42.11 82.77

Price Performance

Historical Comparison
PHUN
VERU

About PHUN Phunware Inc.

Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: